Proteomics Exploration of Chronic Lymphocytic Leukemia

Ti’ara L. Griffen
{"title":"Proteomics Exploration of Chronic Lymphocytic Leukemia","authors":"Ti’ara L. Griffen","doi":"10.31031/nacs.2019.03.000553","DOIUrl":null,"url":null,"abstract":"Chronic Lymphocytic Leukemia (CLL) is an adult heme malignancy characterized by the presence of ma-ture-appearing CD5+ B cells in the blood, bone marrow, and secondary lymphoid organs. CLL is heterogeneous in its progression and clinical outcomes. Factors that contribute to the heterogeneity include the immunoglobulin heavy chain (IGHV) status and chromosomal aberrations. CLL’s heterogeneous behavior has made it difficult to understand its biology and find a cure. Systems biology approaches are commonly used to establish biomarkers for cancer. Because proteins are targets of FDA approved therapies, proteomics approaches have been used to decipher the c mplex behavior of CLL pathogenesis and identify actionable targets. In this minireview, we highlight factors that contribute to CLL, new insights discovered from proteomics studies, and future directions.","PeriodicalId":93131,"journal":{"name":"Novel approaches in cancer study","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Novel approaches in cancer study","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31031/nacs.2019.03.000553","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Chronic Lymphocytic Leukemia (CLL) is an adult heme malignancy characterized by the presence of ma-ture-appearing CD5+ B cells in the blood, bone marrow, and secondary lymphoid organs. CLL is heterogeneous in its progression and clinical outcomes. Factors that contribute to the heterogeneity include the immunoglobulin heavy chain (IGHV) status and chromosomal aberrations. CLL’s heterogeneous behavior has made it difficult to understand its biology and find a cure. Systems biology approaches are commonly used to establish biomarkers for cancer. Because proteins are targets of FDA approved therapies, proteomics approaches have been used to decipher the c mplex behavior of CLL pathogenesis and identify actionable targets. In this minireview, we highlight factors that contribute to CLL, new insights discovered from proteomics studies, and future directions.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
慢性淋巴细胞白血病的蛋白质组学研究
慢性淋巴细胞白血病(Chronic Lymphocytic Leukemia, CLL)是一种成人血红素恶性肿瘤,其特征是血液、骨髓和次级淋巴器官中存在CD5+ B细胞。CLL的进展和临床结果具有异质性。导致异质性的因素包括免疫球蛋白重链(IGHV)状态和染色体畸变。CLL的异质性行为使得了解其生物学并找到治疗方法变得困难。系统生物学方法通常用于建立癌症的生物标志物。由于蛋白质是FDA批准的治疗的靶点,蛋白质组学方法已被用于破译CLL发病机制的c复合物行为并确定可操作的靶点。在这篇综述中,我们重点介绍了导致CLL的因素、蛋白质组学研究的新发现以及未来的发展方向。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
The Applications of Protein Nanomaterials in Cancer Therapies Anti-Inflammatory Responses of Natural Products in Wounds and Cancer Infections Antimicrobial Peptides in Bladder Cancer The Neoplastic Tonnage-Pleomorphic Xanthoastrocytoma Current Therapeutics and Future Perspectives for Treatment of Advanced BRAF V600 mutant Melanoma
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1